14.06.2017 • NewsCPCshale gasPetrochemicals

Taiwan’s CPC Looks to Invest in US Shale

Taiwan’ state-owned energy giant CPC Corp is considering the possibility of investing in shale gas extraction and a petrochemical plant in the US, company chairman Chen Chin-te, told the Taiwan central news agency.

Chen, who is scheduled to depart for the US on Jun. 14 on a fact-finding visit, said CPC and its affiliates would like to invest about $10 billion in the country, with the aim of adopting more advanced technology to produce higher-quality ethylene at a lower cost. During his visit, Chen will be accompanied by minister without portfolio Ho Mei-yueh to explore the possibility of investing in natural gas in Louisiana.

However, an issue of concern is whether petrochemical products from CPC would have a strong market in the US, given President Donald Trump’s stance on making American manufacturing a top priority.

In February, CPC announced it would invest $6.85 billion in Taiwan over the next six years. Projects include a liquefied natural gas (LNG) receiving terminal in Taoyuan City, with operations set to begin in 2023; a second-phase expansion of the Taichung LNG terminal; and upgrading the Taoyuan oil refinery.

In addition, CPC and (undisclosed) partners will jointly provide about $1.2 billion for three facilities to produce hydrocarbon resins, isononyl alcohol and styrene.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.